Latest Cost Control News

Aurelia Metals reports a robust September 2025 quarter, with production and costs aligning to plan and key projects advancing ahead of schedule. Significant growth in copper resources and reserves underpins a confident outlook for FY26 and beyond.

Prospech Limited reports steady progress on rare earth element metallurgy at its Korsnäs project and promising gold-silver drill results in Slovakia, backed by a fully subscribed $2.1 million capital raising.

FortifAI Limited reported steady revenue and significant cost reductions in Q1 FY26, while securing new contracts and advancing AI initiatives to boost operational efficiency.

Coventry Group reports a 4.5% increase in Q1 FY26 sales alongside a notable EBITDA turnaround, underpinned by a $10 million cost-out program and fresh executive appointments.

Enero Group reports improved profitability in FY25 despite revenue decline, driven by divestment and AI innovation, with FY26 Q1 EBITDA up 13%.

Beamtree Holdings has reported a 9% increase in recurring revenue for Q1 FY26, driven by strong contract wins and international expansion, including a key UK NHS partnership and a new autonomous coding rollout.

Vinyl Group Ltd reports a striking 190% revenue surge in FY25 and a record Q1 FY26, setting sights on its first EBITDA-positive quarter by mid-2026.

Vinyl Group Ltd reported a 37% jump in quarterly revenue alongside significant cost reductions, setting the stage for an EBITDA-positive quarter in Q2 FY26. The company also advanced a key equity conversion deal with Songtradr, signaling strategic balance sheet strengthening.

TerraCom Limited has extended the life of its Blair Athol Mine to 2033, supported by a robust 2025 JORC Code Resource and Reserve update. This reinforces the mine’s status as a low-cost, long-life asset underpinning stable cash flow and growth potential.

Austral Gold Limited has released an updated Mineral Resource and Reserve estimate for its Casposo Mine in Argentina, underpinning plans to restart production with strong economic fundamentals. The report highlights a 74-month mine life and a compelling after-tax NPV of US$72.7 million.

Resonance Health reveals a robust growth strategy targeting $17 million revenue by FY26, powered by AI-enhanced medical imaging and global clinical trial services expansion.

Medical Developments International reported a strong start to FY26 with significant revenue growth driven by increased Penthrox volumes and pricing improvements in Australia, alongside steady European demand and progress on paediatric label approvals.